Treatment of Older Patients With Head and Neck Cancer: A Review by VanderWalde, N. A. et al.
ABSTRACT
The incidence of head and neck cancer (HNC) in the elderly is in-
creasing. The treatment of HNC often includes multimodality
therapythatcanbequitemorbid.Olderpatients(herein,defined
as65 years) with HNC often have significant comorbidity and
impairedfunctionalstatusthatmayhindertheirabilitytoreceive
and tolerate combinedmodality therapy. They have often been
excluded from clinical trials that have defined standards of care.
Therefore, tailoring cancer therapy for older patients with HNC
canbequite challenging. In this paper,weperformeda compre-
hensive literaturereviewtobetterunderstandanddiscuss issues
related to therapeutic recommendations that are particular to
patients65yearsandolder.Evidencesuggeststhatolderpatients
have similar survival outcomes compared with their younger
peers; however, they may experience worse toxicity, especially
with treatment intensification. Similarly, older patients may re-
quire more supportive care throughout the treatment process.
Future studies incorporating geriatric tools for predictive and in-
terventionalpurposeswillpotentiallyallowfor improvedpatient
selection and tolerance to intensive treatment. TheOncologist
2013;18:568–578
Implications for Practice: Tailoring therapy for older patients with head and neck cancer (HNC) is challenging. This review
article providesphysicianswithevidenceonhowolderpatientsmaydiffer fromtheiryoungerpeers. Inaddition,weofferclinical
recommendations to guide oncologists on treatment recommendations andmanagement of older HNC patients.
INTRODUCTION
Headandneckcancers (HNC)occurwithintheparanasal sinuses,
nasal cavity, oral cavity, pharynx, and larynx. In2012, therewere
anestimated52,610newcasesofHNCand11,500relateddeaths
in the U.S. [1]. Despite the increasing trend of cancer related to
humanpapillomavirus,which primarily affects younger patients
[2,3],HNCremainsprimarilyacancerofanolderpopulation.Ac-
cording to the Surveillance, Epidemiology, andEndResults data-
base, approximately 47% of all patients diagnosed with HNC in
theU.S.between1973and2008were65[4]. Inaddition,thein-
cidence of newly diagnosed HNC cases among the elderly is ex-
pected to increasebymore than60%by theyear2030 [5].
Treatment paradigms for older patients with HNC are not
well defined. The majority of patients with HNC will present
with advanced (stage III and IV) disease requiringmultimodal-
ity therapy [6]. Combined surgery, radiation, and chemother-
apy cause significant acute toxicity and long-term morbidity,
thus reducing compliance to therapy, quality of life, and life
expectancy. These morbidities can be profound in older pa-
tients, secondary to comorbid medical conditions and im-
paired functional status. Hence, older patients are often
considered poor candidates for multimodality treatment and
are subsequently less likely to receive standard of care ther-
apy compared with younger patients [7, 8]. This bias against
optimal treatmentmay jeopardize their chance of cure. In ad-
dition,olderpatientsareoften ineligible for the largeprospec-
tive randomized trials on which treatment paradigms are
based (Table1) [9–27]. For example, in a recentmeta-analysis
of 93 clinical trials, only 692of 17,346 patients (4%)were70
years of age [28]. Thus, the outcomes of these trials may not
be applicable to older patients. Despite recommendations
not to include age limits in large prospective trials, many
ongoing trials continue to have upper age limits in their in-
clusion criteria. For these reasons, many are concerned
that older patients with HNC have a smaller therapeutic
benefit with treatment intensification comparedwith their
younger peers (Fig. 1) [29].
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Thepurposeof this paper is to review thepublished litera-
ture toattempt toanswer the followingquestionswith regard
to HNC, with an objective to better equip oncologists toman-
age older patients with HNC:
1. Do older patients haveworse survival rates?
2. Do older patients experienceworse toxicities?
3. Should comorbidity influence treatment recommendations?
4. Doolderpatientshaveworsequalityof life after treatment?
5. Do older patients require more supportive care during
treatment?
METHODS
For each subsection of this review, we performed a
PubMed search using the terms “head and neck cancer,”
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Larynx [11]
Definitive sequential chemotherapy
radiation vs. surgery postoperative
radiation






vs. concurrent chemoradiation vs.
radiation alone





and Treatment of Cancer (EORTC)
24954 [13]
Sequential chemotherapy radiation
vs. alternating chemotherapy and
radiation




Tete Et Cou. (GORTEC) [14]
Radiotherapywith concurrent
chemotherapy (carboplatin 5-FU) vs.
radiotherapy alone
OS, DFS, and LCwere all
improvedwith chemotherapy
226 55 (32–74)a
Intergroup trial [15] Radiation alone vs. radiationwith bolus
cisplatin vs. split course RTwith bolus
cisplatin and infusional 5-FU
Did notmeet accrual; OSwas
improvedwith RT and bolus
cisplatin
295 57 (25–80)a
RTOG 97-03 [16] RTwith daily cisplatin and 5-FU vs. RT
with daily hydroxyureawith 5-FU vs. RT
withweekly cisplatin and paclitaxel












Trialsts Group 1 (UKHAN1) Trial
(nonsurgery arms) [18]
RT alone vs. RTwith concurrent
chemotherapy (VBMF orMalone) vs. RT
with adjuvant chemo vs. RTwith
concurrent and adjuvant chemotherapy
Improvement in EFSwith RT
concurrent chemotherapy
713 60 (17–84)





Brizel trial [20] Hyperfractionated RT alone vs.
hyperfractionated RT cisplatin and
5-FU
Improvement in LCwith
chemotherapy and trend in OS,
RFS
122 59a
Jeremic trial [21] Hyperfractionated RT alone vs.
Hyperfractionated RT daily cisplatin




German trial [22] Hyperfractionated RT alone vs.
hyperfractionated RT carboplatin and
5-FU




Swiss trial [23] Hyperfractionated RT alone vs.
hyperfractionated RT cisplatin
LC and DFS improvedwith
cisplatin; no difference in OS or
time to failure
224 55 (33–74)
GORTEC 99-02 [24] Standard fractionated RT concurrent
carboplatin and 5-FU vs. accelerated
hyperfractionated RT concurrent
carboplatin and 5-FU vs. very
accelerated hyperfractionated RT alone





RTOG 9501 [25] RT alone vs. RTwith concurrent cisplatin LC and DFS benefit with
chemotherapy
459 56 (24–80)b
EORTC 22931 [26] RT alone vs. RTwith concurrent cisplatin LC, PFS, andOS improvedwith
chemotherapy
167 54
French trial [27] RT alone vs. RTwith concurrent
carboplatin
No difference 144 55.5a
UKHAN1 trial (surgery arms) [18] RT alone vs. RTwith concurrent VBMF No difference 253 58 (32–81)
aMean age.
bTotal of 25 patients whowere70 years old (5%).
Abbreviations: DMFS, distantmetastases-free survival; ECOG, Eastern Cooperative Oncology Group; EFS, event-free survival; FU, fluorouracil; LC,
local control; LRPFS, local recurrence progression-free survival;M,Methotrexate; OS, overall survival; PFS, progression-free survival; RFS,
recurrence-free survival; RT, radiation therapy; TTP, time to progression; VBMF, vincristine, bleomycine,methotrexate, and fluorouracil.
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“older” or “elderly,” and the topic of each subsection. Rel-
evant prospective and retrospective studies published
from 1980 to 2012 were included. Studies published in lan-
guages other than English or not involving human subjects
were not reviewed. There was no definitive age cutoff used





to have worse survival than their younger peers. The data are
summarized inTable2bymodality andarediscussedbelow.
Surgery
Limited data suggest that selected older patients have survival
outcomes similar to younger patients when treated primarily
with surgery. In particular, a number of retrospective studies
have matched older patients to a younger cohort and have
shownnodifference in survivaloutcome[30–32].Kowalski etal.
matched115patientswhowere70yearsofagebytumor type
and stage to 115 patients70 years of age and found no differ-
ence in 5-year survival rate [30]. In addition, multiple non-
matched retrospective studies have shown similar results [33,
34].
Radiation
Multiple retrospective single-institution studies all indicate
that the oncologic outcomes among older patients receiving
radiotherapy alone are similar to their younger cohorts [35–
41].However, only three studiesdirectly comparedoutcomes
amongdifferent age groups [35, 40, 42]. The first, a secondary
analysis of four prospective European Organization for Re-
search and Treatment of Cancer HNC trials, found no differ-
ence in overall survival among four different age groups,
including patients 75 years [35]. The second study per-
formed a comparison of 39 patients 70 years receiving ac-
celerated concomitant boost radiation with 80 patients 70
years receiving the sameradiation regimen [40]. Therewasno
observed difference in 3-year overall survival or local control
betweenthetwogroups.Thethirdstudyshowedthatage,asa
continuousvariable,hadastatistically significantdetriment to
cause specific survival; however, the effect wasmodest (rela-
tive risk: 1.03) [42].
Chemoradiation
Evidence suggests that older patients may not have a sur-
vival benefit from the addition of chemotherapy to radia-
tion. In a meta-analysis of 93 clinical trials, Pignon et al.
demonstrated that although there appeared to be an over-
all survival benefit of 4.5% at 5 years with the addition of
chemotherapy, this benefit was not evident among older
patients [28]. Specifically, patients age 71 and older had no
statistical benefit in 5-year survival rates with the addition
of chemotherapy. The authors suggest that thismay be due
to the increased rate of noncancer deaths among this co-
hort of older patients, but it may also be due to the small
number of evaluable patients [28].
We identified threeprospective studies that treatedolder
patients with chemoradiotherapy to identify the tolerability
of different chemoradiation regimens [43–45]. Although
these studies showed relatively good short-term survival re-
sults, theydidnot study their regimens inyoungercohortsand
thus do not answer our question. Two retrospective studies
directly compared older cohortswith their younger peers and
suggested no difference in overall survival (OS), disease-spe-
cific survival, or recurrence-free survival among patients70
years [46, 47]. However, an additional retrospective study
suggests a statistically significant decrease in OS among pa-
tients65 years [48]. It is important to note that it is difficult
to compare outcomes among different studies becausemany
of these studies used different chemotherapy regimens even
within the same study. For example, Merlano et al. had a
higher percentage of the older patients receiving cetuximab
andradiationwithahigherpercentageofyoungerpatients re-
ceiving platinum-based chemoradiation [48]. Therefore, al-
though the existing data supports that older patients have
oncologic outcomes to chemoradiation similar to younger pa-
tients, the quality of the data limits the confidence of this asser-
tion.
Conclusion
Surgery, radiation, and chemoradiation appear to be equally
efficacious in older and younger patients. Treatment recom-
mendations should not be influenced by a perception that one
modalitymay not be efficacious in older patients.
Figure 1. Theoretical therapeutic ratio for head andneck cancer
treatment. (A): Younger patients. (B):Older patients.




Table 2. Outcomes and toxicity in elderly specific studies for head and neck cancer





Kowalski et al. [30] Retrospective single
institution
115 pts age70 yr; 115
pts age70 yr (matched)
5-yr survival: 43% for pts
70 yr, 55.6% for pts
70 yr; p .1
No difference in local/systemic
complications or postoperative
deaths
Majority of deaths in both




Clayman et al. [31] Retrospective single
institution
43 pts age80 yr; 79 pts
age65 yr (matched)
Median survival: 34.3mo
for pts80 yr, 42.7mo












McGuirt et al. [32] Retrospective single
institution
217 pts age65 yr, split
into four age groups (65–
71 yr, 72–72 yr, 75–80 yr,
81 yr)
5-yr survival rates: 65–71
yr: 53.4%, 72–74 yr:
58.9%, 75–80 yr: 55.1%,
81 yr: 46.3%; not
significant
Major complications: 65–71 yr:





patients ( 81 yr)
comparedwith youngest
old patients (65–71 yr)
Survival: no; toxicity:
No
Laccourreye et al. [33] Retrospective single
institution
69 pts age65 yr 5-yr actuarial survival:
68%; 5-yr local control:
93.9%
Early surgical: 13.1%; early






Morgan et al. [49] Retrospective single
institution
810 pts age65 yr; 963
pts age65 yr
NA 30-daymortality: 3.5% for pts
65 yr, 0.8% for pts65 yr;
nonlethal complications: 32%




mortality, this was a
nonmatched cohort that
did not account for stage,
type of cancer, baseline




Bridger et al. [51] Retrospective single
institution (free flap
reconstruction)
26 pts age70 yr; 91 pts
age70 yr (matched)
NA Surgical complications: 42% for
pts70 yr, 37% for pts70 yr;
postoperativemedical
complications: 54% for pts









52 pts age70 yr; 35 pts
age70 yr (matched)
NA Major surgical complications:
13% for pts70 yr, 23% for pts
70 yr;minor surgical
complications: 24% for pts
70 yr, 34% for pts70 yr;
majormedical complications:
4% for pts70 yr, 0% for pts
70 yr;minormedical
complications: 7% for pts70
yr, 6% for pts70 yr
No statistical significance
was shown between the
groups, even after
controlling for site, ASA
classification, andmethod
of reconstruction;50%










29 pts age70 yr; 232
pts age70 yr
NA Length of stay (median): 29
days for pts70 yr, 21 days for
pts70 yr; all postoperative
complications: 51% for pts











Zabrodsky et al. [54] Retrospective single
institution









Sanabria et al. [55] Retrospective single
institution













1,589 pts total; 408 pts
(25%) age65 yr
No difference in overall
survival between age
groups
No difference in objective
mucosal reaction, weight loss,
or long-term toxicity, but there
was a difference in functional
mucosal reaction, with an
increase in grade 3–4 toxicity
among the older groups










Lusinchi et al. [36] Retrospective single
institution
331 pts age70 yr; 249
pts had RT alonewith




intent had 71% local
control; 5-yr survival rate
for all patients: 33%
Severemucositis in 17% of
cases; no correlationwith age







Schofield et al. [37] Retrospective single
institution




5-yr OS: 28%; 5-yr CSS:
59%; 5-yr LC: 70%; 5-yr
nodal control: 87%
98% completed RT; severe late
toxicity occurred in 3.1%
Age did not affect cancer
or toxicity outcomes
NA
Zachariah et al. [38] Retrospective single
institution
50 pts with HNC age 80–
94 yr (35 curative intent)
Complete response:
66%; complete or partial
response: 83%
97% completion rate; 66%
grade 2–4mucositis among
curative intent pts
Radiation is a safe
treatment for oldest old
patients
NA
Mitsuhashi et al. [39] Retrospective single
institution
14 pts with HNC age 90–
98 yr; 11 of 14 treated
with curative intent
90% response rate; 60%
complete response rate
90% completion rate among
those treatedwith curative
intent; 4 of 11 pts required 2-
to 3-week break









39 pts age70 yr; 80 pts
age70 yr
3-yr OS: 68% for pts70
yr; 62% for pts70 yr;
LC: 73% for pts70 yr,
68% for pts70 yr
100% completion rate in both
groups; unplanned breaks: 8%
in older group, 0% in younger
group; p .03; no difference in
other acute toxicities
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It stands to reason that patients with medical comorbidities
and poorer functional reserve (common issues in older pa-
tients with HNC) would experiencemore and/or worse treat-
ment-related toxicity. Treatment modality-specific toxicity is
reviewed and summarized in Table 2. The results of these
studies appear to bemixed in their conclusions.
Surgery
Two surgical retrospective series suggested an increased risk
of postoperative mortality in older patients [49, 50]. Morgan
etal. [49]observedan increase in30-daymortality inolderpa-
tients (3.5%mortality) as comparedwith that in a younger co-
hort (0.8%). This study did not match the cohorts by tumor,
stage, comorbidity, or any other risk factors. The authors con-
cludedthat, given therelatively lowrateofperioperativemor-
tality, agealoneshouldnotbeacontraindication toaggressive
surgery. Milet et al. observed age to be associated with post-
operativemortalityonunivariatebutnotmultivariateanalysis
[50].However, anadditional six retrospectivematchedcohort
reviews [30–32, 51–53] and three unmatched retrospective
reviews [33, 54, 55] show no correlation between age alone
and postoperative complications (Table 2).
Radiation
Two retrospective studies that compare older patients with
younger patients suggest an increase inmucositis [35] and/or
unplanned treatment breaks [40] among the older cohorts.
However, other comparative studies appear to show no dif-
ference in acute toxicities or treatment interruptions [36, 42].
Table 2. (continued)




Huguenin et al. [41] Retrospective single
institution
75 pts age75 yr; 17 pts
postoperative, 58 pts
with RT alone




30% of the patients required
treatment interruption
(unknown reasons), 1 case of
late bone necrosis
No comparison to younger
group and no acute
toxicitymentioned
NA
Huang et al. [42] Retrospective single
institution
238 pts age75 yr;
1,249 pts age75 yr;
16% of pts age75 yr




2-yr CSS: 72% for pts
75 yr; 86% for pts75
yr; p .01; RR: 1.03 (per
year)









Tsukuda et al. [43] Prospective
feasibility study





93% for stage III and 54%
for stage IV
36% required nutritional
support andGI tube; 20% had









Koussis et al. [44] Prospective phase II
study
35 pts total; 16 pts age











chemotherapy, 37% had grade
3–4 hematologic toxicity and
57%had grade 3–4GI toxicity;
















3-yr OS: 64%; 3-yr DFS:
58%; LC: 79%
25%had grade 3mucositis;
15% had grade 3 neutropenia;
no grade 4 toxicities; no
patient required
hospitalization; 80% of

















230 evaluable pts; 27 pts
age70 yr; 203 pts age
70 yr
NA Age as a continuous variable
was significantly associated
with late toxicities (OR: 1.05)
Agewas a strong
independent risk factor




Boscolo-Rizzo et al. [57] Retrospective single
institution
44 pts age65 yr;
treatedwith induction
chemotherapy followed
by CRT (cisplatin and 5-
FU)
3-yr OS: 71%; 3-yr PFS:
67%; 3-yr functional PFS:
57%
84% completed induction, RT,
and at least 80% of concurrent
chemotherapy; 66% developed









Michal et al. [46] Retrospective single
institution
44 pts age70 yr; 137
pts age70 yr; RTwith 2
cycles of Cisplatin and
continuous 5-FU; 72% of
younger cohort treated
with b.i.d. RT; only 30%
of older patients treated
with b.i.d. RT
5-yr DSS: 71% for pts
70 yr; 74% for pts70
yr; recurrence-free
survival: 69% for pts70
yr; 71% for pts70 yr













Nguyen et al. [47] Retrospective single
institution
112 total pts; 27 pts age




2-yr OS: 68% for pts70
yr; 74% for pts70 yr
No difference in grade 3–4
toxicity; no difference in
treatment breaks or early
cessation of treatment






Merlano et al. [48] Retrospective single
institution
317 total patients; 93 pts
age65 yr; 224 pts age




(28mo vs. 46mo; HR:
1.51 onmultivariate
analysis; no difference in
response rates
Higher rate of infections (28%
vs. 16%) and pneumonia (11%










Abbreviations: ASA, American Society of Anesthesiologists; CRT, chemoradiotherapy; CSS, cancer-specific survival; DSS, disease-specific survival;
FU, fluorouracil; GI, gastrointestinal; HNC, head and neck cancer; HR, hazard ratio; KPS, Karnofsky Performance Status; LC, local control; NA, not
available; OR, odds ratio; OS, overall survival; PFS, progression-free survival; pts, patients; RR, relative risk; RT, radiotherapy.






ference in treatment interruptions, radiotherapy completion,
treatment-related deaths, or late toxicities [42]. In addition,
three additional studies retrospectively analyzed their out-
comes in their oldest patients (80 years) and demonstrated
acceptable rates of toxicities [37–39].
Chemoradiation
As treatment intensity increases, thepotential forgreater tox-
icity also increases. In a retrospective analysis of three pro-
spective Radiation Therapy Oncology Group (RTOG) studies,
Machtayetal. demonstrated thatageasacontinuousvariable
was significantly associatedwith developing severe late toxic-
ities (odds ratio: 1.05, p .001) [56]. Two retrospective stud-
ies that directly compared toxicity outcomes among older
cohorts with those of younger cohorts demonstrated worse
tolerability and toxicity to treatment. Specifically, they identi-
fied worse compliance with chemotherapy, more unplanned
hospitalizations, increasedmyelosuppresion, increased infec-
tions/pneumonia rates, and longer periods of feeding tube
dependence among the older cohorts [46, 48]. Additional
noncomparative retrospective studies demonstrated high
rates of severe toxicities among older cohorts [57].
Unfortunately, the three prospective trials that ana-
lyzed feasibility of multimodality treatment regimens in
older patient populations do not directly answer our ques-
tion of whether older patients experience worse toxicity. Al-
though they all report relatively similar toxicity profiles to the
larger randomized trials, including younger cohorts [43–45],
they include highly selected patient populations and do not re-
port all relevant toxicities. In particular, one study only reported
toxicities during the induction portion of the treatment regimen
[44].
Cisplatin is the standard chemotherapy to give concur-
rently with radiation. It is common practice to substitute ce-
tuximab with cisplatin in older patients because of perceived
lowertoxicityprofileasobserved intheBonner trial [19].How-
ever, there are now multiple published retrospective studies
that demonstrate either similar or increased rates of mucosi-
tis in patients who receive cetuximab compared with those
who receive cisplatin concurrentwith radiation [58, 59]. Addi-
tionally, a randomized trial undertaken by the Gruppo di Stu-
dio sui Tumori della Testa (GSTTC) Italian Study Group
compared concurrent cetuximab radiation with concurrent
cisplatin radiation with or without induction in a 2 2 design
[60]. Preliminary toxicity resultsdemonstratedsimilar ratesof
mucositis (76% with cetuximab vs. 78% with cisplatin; p 
.63). More patients were able to complete concurrent cispla-
tin compared with cetuximab (93% vs. 81%; p  .01) without
dosemodifications (75% vs. 50%; p .01). Furthermore, me-
diandurationof concurrent radiationwas1week longer in the
cetuximab arm (7 weeks cisplatin versus 8 weeks cetuximab;
p  .01). Thus, concurrent cetuximab may not result in less
acute toxicity [60].
Locally recurrent disease in the setting of previous radi-
ation is a challenge in the older patientwithHNC. Currently,
adjuvant chemotherapy alone is considered standard of
care [61]. Older patients in this setting have worse toxicity
from platinum-based chemotherapy compared with their
younger peers [62]. Prospective clinical trials have shown
that reirradiation with chemotherapy in carefully selected
patients results in poor survival rates and high rates of ma-
jor toxicities. The RTOG has conducted two phase II trials
evaluating the efficacy of reirradiation and chemotherapy:
RTOG 9610 [63] and 9911 [64]. The median age of patients
in these trials were 62 and 60 years. In RTOG 9610, the inci-
dence of severe acute toxicity was 17.7% (grade 4) and 7.6%
(grade5)[63].The2-yearoverallsurvivalestimatewas15.2%and
thecumulativeincidenceofgrade3–4latetoxicitywas9.4%[63].
The follow-up phase II study RTOG 9911 (60 Gywith concurrent
cisplatin and paclitaxel) had higher 2-year overall survival rate
(25.9%)but comparableacutegrade4orworse (28%)andgrade
5 (8%) toxicities [64]. Late toxicities were also significant (34%
grade 3–4, 4% grade 5) [64]. Local regional recurrences after ra-
diotherapycansometimesbesalvagedwithsurgery.Theefficacy
of reirradiation with chemotherapy after salvage surgery has
been evaluated in a randomized trial from France [65]. Theme-
dianageofpatients in this studywasnot reported.Patientswere
randomized to either salvage surgery alone versus salvage sur-
geryandpostoperativechemoradiotherapy.Theadditionofreir-
radiation with chemotherapy after salvage surgery improved
disease-free survival but not overall survival rates. Furthermore,
39% of patients in the chemoradiation arm experienced grade
3–4 late toxicity (comparedwith 10% in the surgery-alone arm)
[65]. In the above trials, highly selected patients (i.e., excellent
performance status, minimal comorbidities) were enrolled; de-
spitecareful selection,outcomeswerepoorandseveretoxicities
were excessive. In older patientswithHNC, it is likely that toxici-
tieswillbeworse.Ourpractice is toavoidreirradiationwhenever
possibleandadvocatesalvagesurgeryalone.Reirradiationisonly
attempted in themost carefully selectedpatients.
Conclusion
Olderpatientsexperiencegreateracuteand late toxicityas the
intensity of treatment increases. Specifically, theadditionof che-
motherapy to radiation increases toxicity and reduces tolerance
to therapy. The belief that cetuximab (when given concurrently
withradiation) is less toxic thancisplatinmaynotbetrue.Re-irra-
diationwith/without concurrent chemotherapy in the recurrent/
previously irradiated setting shouldbeavoided.
Comorbidities and Treatment Recommendations
PatientswithHNCoften have a history of tobacco and alcohol
use andmultiple other chronic illnesses related to these hab-
its. Inastudyofpatientswith laryngeal cancer,65%ofpatients
had some form of comorbid illness and 25% had multiple co-
morbidities [66]. In patients 70 years old, the incidence of
comorbiditieswasashighas75%[67]. Therearemultiple indi-
ces that measure comorbidity and attempt to grade the bur-
den of particular comorbidities. Two of the most well-known
indices are the Adult Comorbidity Evaluation 27 [68] and the
Charlson Comorbidity Index [69].
There aremultiple articles establishing the relationship
between comorbidity and prognosis for older patients with
HNC (Table 3) [70–78]. The association between comorbid-
ity and overall survival found in all of these articles is under-
standable. The greater the severity of the comorbidity, the
more likely a patient is to die of disease unrelated to cancer.
However, multiple studies have also demonstrated worse
disease-specific survival rates or higher odds of disease re-
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currence among patients with worse comorbidity [72, 76,
79]. It is possible that deaths unrelated to cancer are being
misattributed to cancer. Alternatively, patients with more
comorbidities may receive less intensive treatment (i.e.,
physician recommendation or patient preference), leading
to worse disease-related outcomes, or they may receive
more intensive therapy then they can tolerate, leading to
treatment alterations that result in less effective treat-
ment. This may explain the results of the Pignon et al. [28]
meta-analysis, which observed less benefit from intensive
treatment in the elderly.
Conclusion
Older patients with more comorbidities experience more
treatment-related toxicity and poorer outcomes. Intensifica-




Qualityof life isamultidimensional concept that includeseval-
uation of positive and negative aspects of life [80]. Quality of
life refers to “a patient’s appraisal of and satisfaction with
their current level of functioning compared with what they
perceive to be possible or ideal” [81]. The subjective evalua-
tion of patients’ perceptions of their quality of life (as mea-
sured by validated questionnaires) may be especially
challenging in older patients.
Limited data exists on the quality of life of older patients
with any cancer.Manybelieve that older patients suffermore
side effects and toxicities from treatment and therefore have
more difficulty adjusting to their cancer diagnosis. However,
at least one study has shown that physicians tend to overesti-
mate the problems of their older patients with cancers [82].
The samestudy indicated that itwas youngerpatientswho re-
portedmorequality-of-lifedifficulties through treatment. Ina
prospective study on 78 older patients and 105 younger pa-
tients with HNC undergoing surgery, Derks et al. demon-
strated that although older patients had worse physical
functioning prior to treatment, the difference remained con-
stant throughout treatment, indicating that theolderpatients
did not have a higher relative decrease in physical functioning
comparedwith younger patients. In addition, they found that
younger patients reported more pain at 6 months than older
patients [83]. Ina retrospectivestudyof638patients, Laraway
et al. demonstrated that patients older than 65 had better
physical and emotional functioning 1 year after surgery than
younger patients [84].
These findingsmay suggest that older patients experience
less quality-of-life difficulties than their younger peers. Alter-
natively, theymay suggest that older patients are less likely to
report changes inqualityof lifedue todifferences inperceived
expectations.A45-year-oldpatientwhomissedamonthofwork
due to posttreatment pain may score changes in quality of life
worse than a retired 70-year-old patientwith the same pain. Al-
thoughthecurrentdatasuggeststhatolderpatientsdonothave
worse quality of life following treatment, the subjective na-
ture of quality-of-life endpoints makes it difficult for clini-
cians to interpret this data for their individual older
patients.
Conclusion
Theavailabledata suggest thatpatient-reportedqualityof life
is not significantly reduced after treatment in older patients
withHNC.However,wedonot recommendusing thesedata to
inform patient counseling and treatment decisions.
Supportive Care During Treatment
HNC and its therapy are associated with marked symptom
burden and functional impairment [85]. Supportive care is
crucial to enable patients to complete their prescribed treat-
ment course without breaks in treatment and to recover
safely fromtoxicities.Although the term“palliative care” isof-
ten used interchangeably with “supportive care,” we use the
term “supportive care” to mean care that helps patients and
their families copewith cancer and its treatment [86].
Limited data exists on the quality of life of older pa-
tients with any cancer. Many believe that older pa-
tients suffer more side effects and toxicities from
treatment and therefore havemore difficulty adjust-
ing to their cancer diagnosis. However, at least one
studyhasshownthatphysicians tendtooverestimate
the problems of their older patients with cancers.
Table 3. Impact of comorbidity on prognosis for head and neck cancer
Study No. of patients Comorbidity index Median age (yrs) Hazard ratio (95%CI) for survivala
Reid et al. [70] 9,386 CCI Not stated (62% age 66–74 yr) 1.83 (1.64–2.05)
Datema et al. [71] 1,371 ACE-27 Not stated (49% age60 yr) 2.23 (1.73–2.87)
Piccirillo et al. [72] 1,086 ACE-27 Not stated (43% age65 yr) 2.48 (1.77–3.47)
Alho et al. [73] 221 CCI 63 2.1 (1.2–3.7)
Liu et al. [74] 214 CCI 51 2.7 (1.7–4.2)
Chen et al. [75] 182 ACE-27 59.5 2.3 (1.4–3.6)
Paleri et al. [76] 180 ACE-27 65.5 13.55 (4.81–38.15)
Sabin et al. [77] 152 Age-adjusted CCI Not stated 1.57 (1.18–2.08)
Montero et al. [78] 99 WUHNCI Not stated 1.55 (1.09–2.21)
aComparing highest score to lowest.
Abbreviations: ACE-27, Adult Comorbidity Evaluation 27; CCI, Charlson Comorbidity Index; CI, confidence interval;WUHNCI,WashingtonUniversity
Head andNeck Comorbidity Index.




Amyriad of symptoms such as constipation, nausea/vom-
iting, pain,mucositis, and xerostomiaaffect thoseundergoing
treatment for HNC. Each symptom can have a unique presen-
tationand treatment in theolderpatient. There is sparse liter-
ature specific to the supportive care needs of older patients
undergoing chemoradiation.Michal et al. [46] compared tox-
icities in patients older and younger than 70 years who were
receiving concurrent chemoradiation. Patients older than 70
years requiredmoresupportivecare,with89%requiring feed-
ing tube placement, as comparedwith 69% in the younger co-
hort. In a secondary analysis of five cross-sectional studies of
patients with HNC, a statistical correlation between age and
overall symptom burden and nutritional dysfunction during
therapy was reported [85]. Although not specific to patients
withHNC, inaprospectivemulticenterstudy,53%ofolderadults
experiencedat leastonegrade3–5toxicity [88].Theauthorscor-
rectly pointed out that even grade 2 toxicities, which were not
looked at in this study, can dramatically affect the older pa-
tient. Grade 2 diarrhea, for example, could be enough to
compromise an older patient’s volume and electrolyte sta-
tus, whereas the younger patient could more easily com-
pensate.
The use of prophylactic feeding tubes for patients with
HNC is controversial. Many argue that prophylactic place-
ments helps avoid significant weight loss and dehydration
compared with placement of tubes if/when needed (thera-
peutic feeding tubes). Others argue that early placement of
feedingtubesleadstoatrophyoftheswallowingmechanismand
slower regain of swallowing function after treatment. The data
are insufficient to draw definitive conclusions [89]. However, it
has been the authors’ clinical experience that when older pa-
tients require therapeutic feeding tubes, they are often not able
togettheminenoughtimetoavoidtreatmentdelay,hospitaliza-
tions, or significant weight loss. Therefore, it has been the prac-
tice of the authors to place prophylactic feeding tubes in older
patients receiving intensive curative chemoradiation.
The clinician must also be astute to physiologic changes
that influence the older person’s presentation of pain. Pain
perception declines with age, is influenced by comorbidities
and polypharmacy, and is altered with cognitive impairment
or age-related impairments, suchashearing loss [90]. Particu-
larly for the cognitively impaired, more time for evaluation is
needed to facilitate adequate evaluation of symptoms.
Conclusion
OlderpatientswithHNCrequiremore supportive care.Werec-
ommend prophylactic feeding tubes. We also recommend co-
ordinating care with the patient’s other general practitioners
and specialists. Specifically,we recommend increased interval
of follow-up with patients’ other physicians during cancer
treatment. Efforts should be made by the oncologist to com-
municate regularly with other providers.
DISCUSSION
Older patients with HNCmay be different from their younger
peers. It is generallyacceptedthatage isapoorprognostic fac-
tor in the development of HNC [91]. One theory that partially
explains the increasing incidenceof cancer in theelderly is the
prolongedexposure toenvironmental factors suchas tobacco
or alcohol in the setting of immunosenescence [92]. This dif-
ferential in exposures and immunosenescencemay lead tobi-
ological differences in the solid tumors that develop in older
patients compared with their younger peers [93]. These bio-
logical differences could lead todifferences in theway tumors
respond to antineoplastic therapy, possibly leading to worse
survival [94].However, inour comprehensive reviewof the lit-
erature, we found no definitive indication that older patients
haveworse survival.
The retrospective nature of many of the studies reviewed
makes it to difficult to interpret and integrate the findings of
these studies. For example, the radiation studies differ from
the surgical series in their patient populations. The radiation
series included both older [39] and less healthy patients [36];
therefore, thesurvivaloutcomescannotbedirectly compared
with the surgical series. The radiation studies are also hard to
compare because they include different patient ages, differ-
ent tumor sites, and different radiation and chemotherapy
regimens. For example, in one study, as many as 16% of the
older patients received hyperfractionated (twice a day) treat-
ment [42].Our reviewof the literatureontoxicityamongolder
patients was also mixed. Many studies had different defini-
tions of acute toxicity or may not have recorded toxicity well.
Wealsohaveno indication ifolderpatients required increased
supportive care during their treatment compared with
younger patients. This increased supportive care, if received,
may be what allowed older patients to tolerate this often-
morbid treatment.
Tobalance the risks andbenefits ofmoreeffective or toxic
treatment among older patients with comorbidities, we re-
quire better tools to help predict which patients will tolerate
aggressive therapy. There is great interest amonggeriatricon-
cologists in theComprehensiveGeriatricAssessment (CGA) as
atool toassess functionalageandhealthofolderpatients.The
CGA isa seriesof tools andquestionnairesusedbyclinicians to
evaluate an older person’s functional status, comorbidities,
cognition, psychological status, social functioning and sup-
port, nutritional status, and medications [95]. Decreases in
functional status based on poor scores in activities of daily liv-
ing or instrumental activities of daily living onCGAshavebeen
shown to predict for increased toxicities to both chemother-
apy [88] and surgery [96] and predict for changes in planned
treatment regimen [97]. To our knowledge, there are no
published prospective studies on the use of the CGA for pa-
tients with HNC or patients receiving radiation therapy.
However, studies have suggested that the CGA can be used
as a tool to help choose appropriate therapy for individual
patients [91, 98].
With current treatment modalities, older patients
with HNC do not have worse survival rates but may
experience higher treatment-related toxicities than
their younger peers, specifically as the intensity of
treatment increases. Furthermore, comorbidities
and functional age arebetter predictors of treatment
tolerance and development of toxicities compared
with chronological age.
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the benefits of intensive therapy truly outweigh the potential
risks in selected older patients with HNC. Further, older pa-
tients are heterogeneous both in their disease and in their
physiologic ability to tolerate therapy. Thus, prospective stud-
iesof olderpatients areneeded todefinewhicholderpatients
are likely to tolerate intensive chemoradiotherapy. Pending
better data, physicians should counsel older patients, incor-
porating prognosis of disease and the risks of treatment.
Future research should be directed at developing specific
programs for supporting older patients throughout their
treatment. These programs should be aimed at decreasing
hospitalizations and emergency room visits, reducing treat-
ment breaks or incomplete treatments, and providing better
symptom management and satisfaction with treatment.
These include assessing how objective measures of indepen-
dence (e.g., activities of daily living and instrumental activities
of daily living) or social support requirements changeover dif-
ferent treatments.
CONCLUSIONS
Choosing therapy and caring for older patients with HNC is
challenging. It is commonpractice to extrapolate results from
clinical trials with few older patients to guide treatment. Evi-
dence suggests that the therapeutic indexmayshrinkas treat-
ment intensity increases. With current treatment modalities,
older patients with HNC do not have worse survival rates but
mayexperiencehigher treatment-related toxicities than their
younger peers, specifically as the intensity of treatment in-
creases. Furthermore, comorbidities and functional age are
better predictors of treatment tolerance and development of
toxicities comparedwith chronological age.Older patients re-
quire careful multidisciplinary assessment for the need for
supportive care (e.g., prophylactic feeding tubes) to ensure
successful completion of treatment. Ongoing studies explor-
ing the value of geriatric assessments in older patients with
HNC may allow clinicians to better choose treatment regi-
mens and address toxicities during treatment. These tools
may allow clinicians to better triage older patients with HNC
for intensivemultimodality treatment.
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